Evidence map›Paper›PMID 31557880›Full record

ReviewInternational journal of molecular sciences2019

Proteomic Biomarkers of Retinal Inflammation in Diabetic Retinopathy.

Hannah Youngblood, Rebekah Robinson, Ashok Sharma, Shruti Sharma

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
99citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

99 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Metabolomics in Diabetic Retinopathy: A Systematic Review.Investigative ophthalmology & visual science · 2021
    Pooled it
  4. Pooled it
  5. Bibliometric analysis and visualization of inflammation in the field of diabetic retinopathy research (2006-2025).Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

39 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hannah YoungbloodDepartment of Cellular Biology and Anatomy, Augusta University, Augusta, GA 30912, USA. hyoungblood@augusta.edu.
Rebekah RobinsonMedical College of Georgia, Augusta University, Augusta, GA 30912, USA. rebrobinson@augusta.edu.
Ashok SharmaCenter for Biotechnology and Genomic Medicine, Augusta University, Augusta, GA 30912, USA. assharma@augusta.edu.
Shruti SharmaCenter for Biotechnology and Genomic Medicine, Augusta University, Augusta, GA 30912, USA. shsharma@augusta.edu.

Funding

Targeting Interleukin-6 Trans-signaling in Diabetic RetinopathyR01EY026936 · NEI · AUGUSTA UNIVERSITY · PI SHARMA, SHRUTI · 2016 to 2019
$1.5M
NEI NIH HHS R01 EY026936NEI NIH HHS R01-EY026936
6 · The paper itself

Abstract

Diabetic retinopathy (DR), a sight-threatening neurovasculopathy, is the leading cause of irreversible blindness in the developed world. DR arises as the result of prolonged hyperglycemia and is characterized by leaky retinal vasculature, retinal ischemia, retinal inflammation, angiogenesis, and neovascularization. The number of DR patients is growing with an increase in the elderly population, and therapeutic approaches are limited, therefore, new therapies to prevent retinal injury and enhance repair are a critical unmet need. Besides vascular endothelial growth factor (VEGF)-induced vascular proliferation, several other mechanisms are important in the pathogenesis of diabetic retinopathy, including vascular inflammation. Thus, combining anti-VEGF therapy with other new therapies targeting these pathophysiological pathways of DR may further optimize treatment outcomes. Technological advancements have allowed for high-throughput proteomic studies examining biofluids such as aqueous humor, vitreous humor, tear, and serum. Many DR biomarkers have been identified, especially proteins involved in retinal inflammatory processes. This review attempts to summarize the proteomic biomarkers of DR-associated retinal inflammation identified over the last several years.

Indexed as

ProteomeProteomicsBiomarkersBody FluidsDiabetic RetinopathyHumansProtein Processing, Post-TranslationalRetinitisBiomarkersProteomeBiomarkersDiabetic retinopathyProteomicsRetinal inflammation

Identifiers

PMID31557880
PMCPMC6801709

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.